|
Index | - | P/E | - | EPS (ttm) | -4.06 | Insider Own | 0.10% | Shs Outstand | 23.29M | Perf Week | 9.00% |
Market Cap | 25.20M | Forward P/E | - | EPS next Y | -2.31 | Insider Trans | 0.00% | Shs Float | 22.79M | Perf Month | 45.33% |
Income | -85.70M | PEG | - | EPS next Q | -0.78 | Inst Own | 73.00% | Short Float / Ratio | 0.15% / 0.43 | Perf Quarter | 14.54% |
Sales | - | P/S | - | EPS this Y | -248.60% | Inst Trans | -5.93% | Short Interest | 0.03M | Perf Half Y | -14.84% |
Book/sh | 2.88 | P/B | 0.37 | EPS next Y | 42.40% | ROA | -66.00% | Target Price | 4.17 | Perf Year | -71.87% |
Cash/sh | 4.54 | P/C | 0.23 | EPS next 5Y | - | ROE | -78.50% | 52W Range | 0.72 - 5.20 | Perf YTD | 14.74% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -79.04% | Beta | - |
Dividend % | - | Quick Ratio | 7.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | 50.78% | ATR | 0.09 |
Employees | 48 | Current Ratio | 7.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 55.51 | Volatility | 6.33% 11.24% |
Optionable | No | Debt/Eq | 0.44 | EPS Q/Q | -215.70% | Profit Margin | - | Rel Volume | 3.23 | Prev Close | 1.06 |
Shortable | Yes | LT Debt/Eq | 0.44 | Earnings | - | Payout | - | Avg Volume | 78.96K | Price | 1.09 |
Recom | 2.40 | SMA20 | 6.27% | SMA50 | 10.41% | SMA200 | -25.08% | Volume | 98,964 | Change | 2.83% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite